Start here if you're new
what it is
Lemonade sells renters, homeowners, pet, and life insurance through apps and AI tools.
how it gets paid
Last year Lemonade made $738M in revenue. Renters & homeowners was the main engine at $0.35B, or 47% of sales.
why it's growing
Revenue grew 40.2% last year. The $510M top line matters because it shows demand is real.
what just happened
Revenue hit $510M, but EPS was still -$1.96.
At a glance
B balance sheet — gets the job done, barely
65/100 earnings predictability — reasonably predictable
xvary composite: 40/100 — below average
-$1.00 fy2027 eps est
$1B fy2027 rev est
What they do
Lemonade sells renters, homeowners, pet, and life insurance through apps and AI tools.
You buy insurance on a phone, not through a branch. Lemonade keeps about 25% of premiums (your insurance payments) as its fee, so your money pays software, not a big agent network. With $738M in annual revenue and 1,225 employees, the company runs light compared with old insurers.
How they make money
$738M
annual revenue · their business grew +40.2% last year
Renters & homeowners
$0.35B
Pet insurance
$0.17B
Life insurance
$0.12B
Auto insurance
$0.06B
Other fees
$0.04B
The products that matter
digital insurance platform
core insurance book
$738M total revenue · +40.2% growth
snapshot data does not split the business into clean product buckets. what matters is the whole book: $738M in revenue, fast growth, and no trailing p/e because earnings are still negative.
scale first
future earnings case
operating leverage
fy2027 EPS est -$1.00
the investment case lives here. if scale is real, losses shrink as revenue approaches the $1B fy2027 estimate. if scale is not enough, growth stays expensive and the stock stays hard to value.
unproven
shareholder experience
stock volatility
$24–$100 range · 5 / 100 price stability
you are not buying a sleepy insurer. the stock has traded through a $76 spread in the last 52 weeks, which means sentiment moves faster than fundamentals here.
high drama
Key numbers
$0.74B
annual revenue
This is the size of the business. It is up 40.2% from last year, which is why the stock gets attention.
$57
18-mo target
This sits below your $63.76 price, so the market is paying more than the target says it should.
2.25
beta
A 10% market move can turn into a 22.5% stock move. That is why this name feels loud.
$1.80
FY2026 EPS
The company is still losing money, even after the forecast improved from -$2.45 in FY2025.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- return on equity 26% — $0.26 profit for every $1 investors have put in
B — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in LMND 3 years ago → it's now worth $38,230.
The index would have given you $13,880.
source: institutional data · total return
What just happened
missed estimates
Revenue hit $510M, but EPS (earnings per share) was still -$1.96.
Revenue rose 162% vs. prior year. Losses stayed wide, which is the price of growth.
$0.51B
revenue
$1.96
eps
n/a
n/a
the number that mattered
The $510M top line matters because it shows demand is real, even while earnings are still negative.
-
lemonade likely posted strong growth in 2025. (full-year results were due shortly after we went to press.) should our estimates hold true, we expect that the company saw 39% top-line growth and a continued upward trend in the bottom line.that said, the company remains unprofitable, and despite its current trajectory, we do not foresee that changing this year or next. although lemonade’s inforce premium has been growing at an increasing rate, even as its loss ratio continues to improve, the costs associated with the company’s continued expansion efforts eat up a significant portion of those gains. for reasons discussed in detail below, lemonade’s management likely knows that the company has a limited window of opportunity and is attempting to push forward quickly to capitalize on it, at the cost of delaying profitability.
-
larger insurance companies have begun moving into the artificial intelligence (ai) space.back when lemonade first launched in 2015, the concept of using ai to set premiums and process claims was a novel one. more than a decade on, however, ai has become far more mainstream, with many companies, including larger, established insurance providers, seeking to use it in their operations. in theory, this may pose an obstacle for lemonade, as the company loses its main point of distinction from its older competitors.
-
however, we think that lemonade still possesses some distinct advantages.research shows that the main stumbling block for companies’ use of ai is the failure to integrate it well, and in that regard, the fact that lemonade was built from the ground up with ai in mind is a significant leg up. likewise, the company is free from some forms of standard industry baggage, such as insurance agents, which it replaces with alternative financial arrangements to capture many of the same benefits while keeping operations centralized, allowing for better ai integration. innovations such as special rates for self-driving vehicles should also help the company defend its niche. although we like the company’s prospects, we recommend holding off for now, as hype around ai has driven up the stock’s price.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk is the path to profitable underwriting at scale.
med
profits keep getting pushed out
fy2027 EPS still sits at -$1.00. If that estimate stays negative as revenue approaches $1B, the growth story starts to look like a treadmill.
impact: no trailing p/e today means the stock has little valuation support if investors stop paying for future earnings.
med
the stock is built for violent repricing
Price stability is 5 / 100 and the 52-week range runs from $24 to $100. That is not noise. That is the product.
impact: sentiment shifts can erase gains long before the business case changes.
med
analyst targets do not leave much room for error
The 3–5 year midpoint target is $57, below the current $63.76 share price. You are already above the middle of the long-range case.
impact: even solid execution can disappoint if the stock price arrived before the earnings did.
med
balance sheet quality is good, not elite
A B balance sheet grade keeps funding risk out of the headlines, but it does not give the company endless room to absorb bad insurance periods.
impact: if claims or growth costs run hot at the same time, financial flexibility matters fast.
If LMND reaches the $1B revenue mark and still posts -$1.00 EPS, you are left owning a $5B company that is large enough to matter and still not profitable enough to value with comfort.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
$738M revenue is the part working
Growth of 40.2% from last year is the headline that keeps the story alive. If that slows hard before profits arrive, the stock loses its best defense.
risk
fy2027 EPS still shows a loss
-$1.00 is the number that matters. Until that turns positive, you are underwriting a promise, not a finished earnings model.
trend
institutions have bought for two straight quarters
158 buyers versus 118 sellers in 3q2025 says the stock still has support. Watch whether that appetite survives if estimates stop improving.
valuation check
the midpoint target is below the stock
A $57 midpoint against a $63.76 share price means expectations are already ahead of consensus. You do not have much room for a mediocre quarter.
Analyst rankings
earnings predictability
65 / 100
in human-speak, estimates are not wild guesses, but this is still far from a steady compounder.
risk rank
4
Safer than 20% of stocks means safer than very little. This is not where you hide in a rough tape.
price stability
5 / 100
That score tells you the stock moves first and explains itself later. Size your thesis, not just your excitement.
source: institutional data
Institutional activity
institutions have been net buying for 2 consecutive quarters — 158 buyers vs. 118 sellers in 3q2025. total institutional holdings: 44.3M shares. net buying for 2 quarters.
source: institutional data
Price targets
3-5 year target range
$21
$92
$64
current price
$57
target midpoint · 11% from current · 3-5yr high: $90 (+40% · 9% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive